5 completed, 3 terminated, 1 withdrawn. 6 Phase 2, 2 Phase 1, 1 Phase 3.
By phase and status
Follow EC145: new trials by email Literature Review of EC145 trials Research Report on EC145
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|
Safety and Efficacy Study of Vintafolide and Vintafolide Plus Paclitaxel Compared to Paclitaxel Alone in Participants With Triple Negative Breast Cancer (TNBC) (MK-8109-004)
Vintafolide 2.5 mg, Paclitaxel 80 mg/m^2, Etarfolatide - Breast Neoplasms | Phase 2 | Withdrawn | Endocyte | | 2014-04-01 | 2014-12-19 |
A Study of Vintafolide (MK-8109) in Participants With Advanced Solid Tumor (MK-8109-011)
Vintafolide - Solid Tumor | Phase 1 | Terminated | Endocyte | 3 | 2014-02-01 | 2015-02-10 |
A Study of MK-8109 (Vintafolide) Given Alone or With Chemotherapy in Participants With Advanced Cancers (MK-8109-001)
Vintafolide, Carboplatin, Paclitaxel - Advanced Cancer | Phase 1 | Terminated | Endocyte | 37 | 2012-12-01 | 2015-02-10 |
Study for Women With Platinum Resistant Ovarian Cancer Evaluating EC145 in Combination With Doxil® (PROCEED)
EC145, Pegylated Liposomal Doxorubicin (PLD/Doxil®/Caelyx®), placebo - Ovarian Cancer | Phase 3 | Terminated | Endocyte | 441 | 2011-04-22 | 2021-09-30 |
Phase 2 Study of EC145 Alone Versus EC145+Docetaxel Versus Docetaxel Alone in Participants With FR(++) 2nd Line Non Small Cell Lung Cancer
EC145, EC145 + Docetaxel, Docetaxel - Non Small Cell Lung Cancer | Phase 2 | Completed | Endocyte | 203 | 2011-03-01 | 2021-04-01 |
Extension Study of EC145 (Vintafolide) for Subjects Enrolled in a Previous Study With EC145 (MK-8109-010)
EC145 - Solid Tumors | Phase 2 | Completed | Endocyte | 1 | 2009-12-31 | 2021-04-08 |
Platinum Resistant Ovarian Cancer Evaluation of Doxil and Vintafolide (MK-8109, EC145) Combination Therapy (8109-009, EC-FV-04)
Vintafolide, pegylated liposomal doxorubicin (PLD), EC20 - Ovarian Cancer | Phase 2 | Completed | Endocyte | 162 | 2008-09-01 | 2015-01-07 |
Study of Vintafolide (MK-8109, EC145) in Participants With Advanced Ovarian and Endometrial Cancers (MK-8109-007, EC-FV-02)
Vintafolide, Ertafolide - Ovarian Cancer, Endometrial Cancer | Phase 2 | Completed | Endocyte | 49 | 2007-08-01 | 2015-01-07 |
Study of Vintafolide (MK-8109, EC145) in Participants With Progressive Adenocarcinoma of the Lung (MK-8109-008, EC-FV-03)
Vintafolide, Etarfolatide - Adenocarcinoma of the Lung | Phase 2 | Completed | Endocyte | 43 | 2007-08-01 | 2015-02-27 |
Conditions studied
Neoplasms (5) · Adenocarcinoma (3) · Carcinoma, Non-Small-Cell Lung (3) · Ovarian Neoplasms (3) · Adenocarcinoma of Lung (1) · Breast Neoplasms (1) · Endometrial Neoplasms (1)
Sponsors
Endocyte (9)
Countries
United States (1)
Top investigators
Binh Nguyen, MD, PhD (2) · Binh Nguyen, MD (1) · Siu-Long Yao (1)
Results publications
PMID 24127448, PMID 24667717, PMID 37407274